Home > Insider Trading > Filing (0001104659-23-126508)

Filing Details

Accession Number:: 0001104659-23-126508
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-15 19:40:50
Reporting Period:: 2023-12-13

Accepted Time:: 2023-12-15 19:40:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1722964	Y-Mabs Therapeutics Inc.	YMAB	Pharmaceutical Preparations (2834)	474619612

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753224	Thomas Gad	C/O Y-Mabs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York NY 10169	Chief Business Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-12-13	50,000	$6.58	365,032	No	4	S	Indirect	By GAD Enterprises LLC
Common Stock	Disposition	2023-12-14	50,000	$6.83	315,032	No	4	S	Indirect	By GAD Enterprises LLC
Common Stock	Disposition	2023-12-15	50,000	$6.61	265,032	No	4	S	Indirect	By GAD Enterprises LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By GAD Enterprises LLC
No	4	S	Indirect	By GAD Enterprises LLC
No	4	S	Indirect	By GAD Enterprises LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	60,000	Indirect	By Children
Common Stock	90,500	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $6.355 to $6.83, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
This transaction was executed in multiple trades at prices ranging from $6.75 to $7.14. The price reported reflects the weightedaverage sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holderof the Issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $6.49 to $6.78, inclusive. The price reported reflects theweighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or asecurity holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
Represents 50,000 shares of Common Stock owned by Reporting Person as well as 40,500 restricted stock units ("RSUs") granted tothe Reporting Person on January 17, 2023 pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSUrepresents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on eachof January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on eachvesting date.